BioSpace News Archive

Andrew Alliance and Brooks Life Sciences announced a co-marketing relationship that will enable Brooks Life Sciences consumables to be added to Andrew Alliance’s groundbreaking OneLab software environment, developed to support the design, execution and sharing of life science experiment protocols.

dMed Biopharmaceutical Co., Ltd. recently announced completion of a nearly US$50 million Series B financing, led by Vivo Capital and joined by Legend Capital, Qiming Venture Partners and Lilly Asia Ventures.

Utilizing the capability of one’s own immune system to tackle cancer, an out-of-the box idea was the brain child of Dr. Steven Rosenberg almost three decades ago.

CertainT Platform Complemented by Stable-Isotopic Indicators Offers Brand Owners Increased Supply Chain Transparency and Product and Process Authentication

Eli Lilly and Company announced top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX compared to FOLFOX alone in patients with metastatic pancreatic cancer whose disease had progressed during or following a first-line gemcitabine-containing regimen.

Sol-Gel Technologies, Ltd. announced it will present research on the use of its proprietary microencapsulation technology in treating papulopustular rosacea, including Phase 3 results for Epsolay® microencapsulated benzoyl peroxide cream, 5%, at the 39th Annual Fall Clinical Dermatology Conference® October 17-20 in Las Vegas, Nevada.

Axsome Therapeutics, Inc. announced the completion of patient enrollment in the GEMINI study, a Phase 3, randomized, double-blind, placebo-controlled trial of AXS-05 in patients with major depressive disorder AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.

Palatin Technologies, Inc. announced that data from two pivotal, double-blind placebo-controlled Phase 3 trials and the Exit Survey/Interview data on Vyleesi™ for hypoactive sexual desire disorder will be presented at the 13th European Society of Gynecology Conference in Vienna, Austria.

ArQule, Inc. announced it will report financial results for the third quarter of 2019 before the market opens on Wednesday, October 30, 2019.

miRagen Therapeutics, Inc. announced new data from two Phase 1 clinical trials of MRG-110, miRagen’s microRNA-92 inhibitor, in which administration of MRG-110 was observed to increase angiogenesis, as demonstrated by increased perfusion and histological markers of neoangiogenesis, as well as reduce alpha-smooth muscle actin expression, which has been show to correlate with activation of myofibroblasts.